Results 1 to 10 of about 8,676,773 (167)

Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate [PDF]

Nature and Science of Sleep, 2023
Logan D Schneider,1 Anne Marie Morse,2 Michael J Strunc,3 Joyce K Lee-Iannotti,4 Richard K Bogan5 1Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA; 2Janet Weis Children’s Hospital, Geisinger ...
Schneider LD, Morse AM, Strunc MJ, Lee-Iannotti JK, Bogan RK   +4 more
doaj   +7 more sources

Dosing Optimization of Low-Sodium Oxybate in Narcolepsy and Idiopathic Hypersomnia in Adults: Consensus Recommendations [PDF]

Neurology and Therapy
Introduction Low-sodium oxybate (LXB) is approved for treatment of narcolepsy in patients aged 7 years and older and treatment of idiopathic hypersomnia in adults. LXB contains the same active moiety with 92% less sodium than sodium oxybate (SXB). As the
Anne Marie Morse, Richard K. Bogan, Asim Roy, Michael J. Thorpy   +3 more
doaj   +4 more sources

Effectiveness and Safety of Low-Sodium Oxybate in Participants with Narcolepsy: Primary Results from the DUET Study [PDF]

Neurology and Therapy
Introduction A phase 4, prospective, open-label study of low-sodium oxybate (LXB) in narcolepsy (type 1 [NT1] or 2 [NT2]) or idiopathic hypersomnia included novel symptom outcomes important to patients (Jazz DUET; NCT05875974; registered 16 May 2023 ...
Logan D. Schneider, Chad M. Ruoff, David T. Plante, Deborah A. Nichols, Teresa L. Steininger, Douglas S. Fuller, M. Todd Kirby, Sarah Akerman, Jessica K. Alexander, Marisa Whalen, Alyssa Cairns   +10 more
doaj   +3 more sources

A Patient-centric Clinical Trial Design to Comprehensively Evaluate Low-Sodium Oxybate in People with Idiopathic Hypersomnia or Narcolepsy [PDF]

Neurology and Therapy
Introduction Low-sodium oxybate (LXB; Xywav®) is approved to treat idiopathic hypersomnia in adults and excessive daytime sleepiness or cataplexy in individuals aged ≥ 7 years with narcolepsy.
Deborah A. Nichols, Teresa L. Steininger, Douglas S. Fuller, M. Todd Kirby, Emily C. Barker, Marisa Whalen, Jessica K. Alexander, Sarah Akerman, David T. Plante   +8 more
doaj   +4 more sources

Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy. [PDF]

Hypertension
BACKGROUND: People with narcolepsy are at increased risk for hypertension and cardiovascular disease; excessive sodium intake is linked to both. METHODS: We studied patients with narcolepsy and office systolic blood pressures (BPs) of ...
White WB, Kovacs RJ, Alexander JK, Baranak C, Nichols DA, Fuller DS, Dai J, Whalen M, Ajayi A, Hutchinson B, Dauvilliers Y, Somers VK.   +11 more
europepmc   +3 more sources

Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy. [PDF]

CNS Drugs, 2023
The safety and efficacy of low-sodium oxybate (LXB; Xywav®) were established in a randomized, double-blind, placebo-controlled, phase 3 withdrawal study in adults with narcolepsy with cataplexy; however, the longer-term safety profile has not yet been examined.
Bogan RK, Foldvary-Schaefer N, Skowronski R, Chen A, Thorpy MJ.   +4 more
europepmc   +3 more sources

Stimulating amyloid-β clearance in cerebral amyloid angiopathy with low-sodium oxybate and/or non-invasive vagus nerve stimulation (Clear-Brain): study protocol for a randomised pre-post trial [PDF]

BMJ Open
Introduction Cerebral amyloid angiopathy (CAA) is caused by the accumulation of amyloid-beta (Aβ) in the cerebrovasculature. The glymphatic system is thought to be involved in the clearance of cerebral waste products, including Aβ.
Marianne A A van Walderveen, Marcel M Verbeek, Erik W van Zwet, Marieke J H Wermer, Adriaan C G M van Es, Matthias J P van Osch, Rolf Fronczek, Ellis S van Etten, Lydiane Hirschler, Sanne E Schriemer, Gert Jan Lammers, Eric J Liebler, Annelies M Slats   +12 more
doaj   +2 more sources

Effectiveness and Safety of Low-Sodium Oxybate in Participants with Idiopathic Hypersomnia: Primary Results from the DUET Study. [PDF]

CNS Drugs
Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) was a phase 4, prospective, multicenter, single-arm, open-label, multiple-cohort study of individuals with idiopathic hypersomnia or narcolepsy evaluating safety and effectiveness of low-sodium oxybate (LXB; Xywav®) treatment on sleep and daytime symptoms.
Plante DT, Cairns A, Schneider LD, Nichols DA, Steininger TL, Fuller DS, Kirby MT, Akerman S, Alexander JK, Whalen M, Ruoff CM.   +10 more
europepmc   +3 more sources

Current knowledge on the pathophysiology of idiopathic hypersomnia and potential mechanisms of action for low-sodium oxybate treatment. [PDF]

J Clin Sleep Med
We sought to elucidate hypotheses for the pathophysiology of idiopathic hypersomnia and discuss the mechanisms by which low-sodium oxybate (LXB) improves idiopathic hypersomnia symptoms.Published literature on idiopathic hypersomnia sleep abnormalities, symptoms, treatments, and underlying pathophysiology was reviewed.Patients with idiopathic ...
Schneider LD, Cairns A, Ruoff C, Bogan RK.   +3 more
europepmc   +3 more sources

Effectiveness and optimization of low-sodium oxybate in participants with narcolepsy switching from a high-sodium oxybate: data from the Substitution of Equal Grams of Uninterrupted Xyrem to Xywav study. [PDF]

J Clin Sleep Med
Low-sodium oxybate (LXB; calcium, magnesium, potassium, and sodium oxybates; Xywav) contains the same active moiety as high-sodium oxybates (SXBs; SXB [Xyrem] and fixed-dose SXB [Lumryz]), with 92% less sodium, and is approved in the United States for treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with ...
Macfadden W, Leary EB, Fuller DS, Kirby MT, Roy A.   +4 more
europepmc   +3 more sources